Tag: pharmaceuticals

Pharmaceutical giant Takeda is expanding its AI-driven drug discovery efforts by entering into a significant multi-year research collaboration with Nabla Bio. This partnership, potentially worth over $1 billion, will leverage Nabla Bio's proprietary generative AI platform, JAM, for the *de novo* design of antibodies and other protein therapeutics, aiming to accelerate the development of novel treatments for challenging diseases.

Insilico Medicine is challenging the status quo in AI drug discovery by emphasizing measurable benchmarks over industry rhetoric. CEO Alex Zhavoronkov advocates for a competitive approach, focusing on tangible results like faster, cheaper, and higher-quality drug development, rather than speculative claims. The company

The pharmaceutical industry is undergoing a profound transformation with the advent of AI agents, which are dramatically accelerating drug discovery and development. These autonomous systems are moving beyond data analysis to actively generate hypotheses, design novel molecules, and orchestrate complex experimental workflows, promising to bring life-saving therapies to market faster and more efficiently.

Agentic AI is poised to revolutionize the commercial pharmaceutical landscape, moving beyond simple automation to autonomous action. A new report highlights widespread adoption, with a focus on market intelligence, patient support, and compliance, while also identifying key challenges in workflow design and data integration. This technology promises to transform workflows, enhance productivity, and foster a new era of human-AI collaboration in the industry.